Report Details

Global Autotransfusion Systems Market Size, Share, Forecast Report, 2020-2027

The global autotransfusion systems market is estimated to grow at a CAGR of 5.6% during the forecast period. The major factors contributing to the market growth include the rising number of surgeries, increasing demand for organ transplantation, and emerging focus on patient blood management. The rising number of organ transplantation procedures have witnessed over the years. For instance, as per the Global Observatory on Donation and Transplantation (GODT), in 2017, the number of organs transplanted was 139,024, which increased to 7.3% over 2015. There were 16 transplants per hour in 2017. Of these, 90,306 kidney transplants and 32,348 liver transplants were performed in 2017. This rising demand for organ transplants is leading to increasing demand for autologous blood transfusion for patients' blood management during the organ transplantation procedure.

Autologous blood transfusion has been increasingly gaining significance owing to the growing concerns of blood shortage and blood transfusion safety. With the advances in blood conservation methods, blood transfusion medicine, blood component separation technology, and continuous growth in clinical needs, the scope of ABT technology has been broadened and innovated to a significant extent. There is a significant need for management of blood loss in organ transplantation procedure. As a result, autologous transfusion is utilized as a strategy to minimize the incidence of the harmful effects of allogeneic transfusion. The method is employed to avoid the extreme use of donated blood.

Preoperative autologous transfusion involves collecting patients' blood and stored for a period of time. As there is no determined date for liver transplants, excluding cases which involve living donors, blood collection in advance is normally not feasible. Therefore, intraoperative blood salvage autotransfusion (IBSA) is employed as a strategy for autologous transfusion. IBSA involves the recovery of blood loss during the procedure and returns it to the patients' body by infusion. This eliminates the need for an allogeneic blood transfusion which may have an impact on recipient survival and an immunosuppressive effect. Allogeneic transfusion increases the risk of transmission of viral infections and transfusion errors among patients. This, in turn, is contributing to the demand for autotransfusion systems in organ transplant procedures to manage blood loss and increasing safety and effectiveness during the procedure.


The global autotransfusion systems market is segmented based on application and type. Based on application, the market is classified into orthopedic surgery, cardiac surgery, trauma procedures, organ transplantation, and other procedures. Based on type, the market is classified into autotransfusion products and accessories.

Cardiac surgeries held a significant share in the application segment

The rising number of cardiac surgeries coupled with significant blood loss during the procedure is primarily strengthening the demand for autotransfusion systems in cardiac surgeries. The autologous transfusion is an easy valuable concept to save blood and minimize the transfusion requirement in the post-operative period in cardiopulmonary bypass and open-heart surgeries. It minimizes the requirement for allogeneic blood products in adult cardiac surgery. Preoperative autologous is a safe and efficient option to allogeneic transfusion.Patients suffering from rare blood phenotypes or allogeneic antibodies is expected to have a benefit from autologous transfusion as compatible allogeneic blood may not be always available.

The allogeneic transfusion is associated with potential complications that can be removed or reduced while autologous blood is administered. These complications include alloimmunization, transfusion-transmitted infectious diseases, hemolytic reactions, and allergic and febrile reactions. The withdrawal of autologous blood earlier conducting cardiopulmonary bypass preserve red cell mass protects the platelets, and decrease allogeneic transfusion needs. The appropriate condition for autologous blood donation is elective cardiac surgery where there is a high probability of blood transfusion.

Regional Outlook

Geographically, the global autotransfusion systems market is segmented into North America, Europe, Asia-Pacific, and RoW. North America has witnessed potential in the market owing to the increasing prevalence of chronic diseases, including CVD and cancer and significant blood management programs in the programs. Several universities and hospitals have focused on blood management programs to maintain safety and efficiency in the procedure. For instance, in 2010, Mayo Clinic implemented a patient blood-management program and has since experienced a 35%decrease in blood transfusions, increasing patient outcomes and achieving considerable savings. This, in turn, is contributing to the demand for autotransfusion systems to reduce the need for donated blood and eliminates the detrimental effects of allogeneic transfusion.

Asia-Pacific is expected to witness significant growth during the forecast period

Asia-Pacific is estimated to show significant growth during the forecast period owing to the increasing number of multi-specialty hospitals and rising incidences of orthopedic and CVD in the region. In addition, growing medical tourism is expected to offer an opportunity for market growth in the region.India Brand Equity Foundation (IBEF) estimated that the medical tourism market in India was valued $3 billion in 2017. During the period, 2018-2019, Indian medical tourism market is expected to double owing to the easier norms for medical visa approvals.the number of Foreign Tourist Arrivals (FTAs) in India on medical visa increased 15.9% year-on-year to an estimated 495,056 in 2017 from 427,014 in 2016.

In India, the Joint Commission International (JCI) - accredited hospitals are 21 and are growing significantly. The presence of skilled pediatric experts in India is further attributing to the positive demand for congenital heart disease market. As per Indian Pediatrics, currently, India has approximately 130 pediatric cardiologists and 110 pediatric cardiac surgeons. As a large number of infants are born with congenital heart defects globally, the availability of skilled cardiac surgeons and the cost-effective and reliable treatment is estimated to contribute to the growth of medical tourism in the country. This, in turn, is encouraging hospitals to focus on patient safety and thereby contributing to the demand for autotransfusion system to manage patients' blood.

Competitive Landscape

The major players in the market include Medtronic plc, Fresenius Kabi AG, Becton, Dickinson & Co., LivaNova PLC, and B. Braun Melsungen AG. The marketplayers are adopting strategies such as mergers and acquisitions and product launches, to expand market share and gain a competitive advantage over their competitors. For instance, in April 2019, Ecomed Solutions launched HEMAsavR, a device for blood capture and transfer that will support medical professionals decrease complex and costly allogeneic blood transfusions. It is universally compatible with surgical suction and autologous transfusion systems, which makes it easy to integrate into current protocols. It is primarily beneficial to hospitals that perform orthopedic,cardiac, vascular, trauma, organ transplant, obstetrics/gynecology, thoracic, neurosurgery, general, and urology procedures.